Darya-Varia Executive and Leadership Team

Celso Lim, the Chief Financial Officer at Darya-Varia, directs all fiscal planning and capital allocation strategies. Overseeing the financial health of the organization, the Chief Financial Officer manages budgetary frameworks for the Gunung Putri and Citeureup plants. This leadership role involves optimizing procurement costs for raw materials and packaging to ensure long-term profitability. By analyzing market trends across the domestic and international pharmaceutical sectors, Celso Lim secures the necessary funding for technology transfers and pilot trials. The Chief Financial Officer maintains strict compliance with Integrated Management Systems, ensuring that financial reporting aligns with ISO certification standards. Through precise fiscal oversight, Lim supports the expansion of the Toll Manufacturing business. This executive function directly impacts the ability of the company to deliver high-quality health products while maintaining a robust balance sheet for future growth initiatives within the competitive Indonesian healthcare market.

Clinton Hess, the President & Commissioner at Darya-Varia, architects the overarching corporate governance framework and strategic vision. Overseeing the alignment between the board and executive management, the President & Commissioner ensures that all operational activities adhere to the mission of building a healthier Indonesia. This leadership role involves evaluating the performance of the Citeureup and Gunung Putri plants against international quality benchmarks. By guiding the long-term direction of the company, Clinton Hess fosters collaboration with affiliated entities like PT Medifarma Laboratories. The President & Commissioner monitors the implementation of the halal guarantee system across all manufacturing facilities to maintain consumer trust. Through consistent engagement with stakeholders, Hess drives the strategic expansion of export operations. Ultimately, the President & Commissioner secures the organizational integrity required to sustain 45 years of progress in providing high-quality health facilities to the public.

Ian Kloer, the President & Director at Darya-Varia, executes the daily operational strategy and manages the production output of all pharmaceutical facilities. Overseeing the manufacturing of soft gelatin capsules, sterile injections, and solid preparations, the President & Director ensures that every process meets ISO 9001:2015 and ISO 22000:2018 standards. This leadership role involves coordinating technology transfers and stability studies to maintain product efficacy. By supervising the integration of the halal guarantee system, Ian Kloer guarantees that all finished goods meet strict safety and religious compliance requirements. The President & Director collaborates with the board to refine the Toll Manufacturing business model for both domestic and international markets. Through the management of pilot trials and commercial production cycles, Kloer optimizes the efficiency of the Gunung Putri and Citeureup plants. This executive function directly supports the company goal of delivering quality health solutions to every individual.

Sancoyo Antarikso, the Independent Commissioner at Darya-Varia, provides objective oversight and ensures the protection of shareholder interests. Overseeing the adherence to corporate governance codes, the Independent Commissioner evaluates the effectiveness of the Integrated Management System implemented at the Citeureup and Gunung Putri plants. This leadership role involves reviewing the strategic decisions made by the executive team regarding technology transfers and raw material procurement. By maintaining an impartial perspective, Sancoyo Antarikso strengthens the transparency of the company operations. The Independent Commissioner monitors the progress of the Toll Manufacturing business to ensure alignment with the broader mission of building a healthier Indonesia. Through rigorous assessment of risk management and compliance with SNI ISO/IEC 17025:2017, Antarikso supports the maintenance of high-quality standards. This executive function provides the necessary checks and balances to sustain the long-term reputation of the company within the pharmaceutical industry.